Featured Publications
Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial
Dwyer JB, Landeros-Weisenberger A, Johnson JA, Londono Tobon A, Flores JM, Nasir M, Couloures K, Sanacora G, Bloch MH. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. American Journal Of Psychiatry 2021, 178: 352-362. PMID: 33653121, DOI: 10.1176/appi.ajp.2020.20010018.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionDepression Rating ScaleIntravenous ketamineClinical trialsAdolescent treatment-resistant depressionAdult treatment-resistant depressionPlacebo-controlled clinical trialSignificant short-term efficacySerious adverse eventsPrimary outcome measureSingle intravenous infusionChildren's Depression Rating ScaleCrossover clinical trialShort-term efficacyMajor depressive disorderSingle ketamine infusionSymptoms 24 hoursLater time pointsKetamine’s safetyAdverse eventsAntidepressant medicationKetamine infusionPediatric populationSignificant morbidityIntravenous infusionAnnual Research Review: Defining and treating pediatric treatment‐resistant depression
Dwyer JB, Stringaris A, Brent DA, Bloch MH. Annual Research Review: Defining and treating pediatric treatment‐resistant depression. Journal Of Child Psychology And Psychiatry 2020, 61: 312-332. PMID: 32020643, PMCID: PMC8314167, DOI: 10.1111/jcpp.13202.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionMajor depressive disorderAdolescent treatment-resistant depressionRisk factorsAdolescent major depressive disorderPsychotherapy treatment trialSecond-line treatmentSignificant risk factorsPediatric clinical trialsSecond leading causeSignificant health problemEvidence-based psychotherapiesCent of adolescentsMedication switchAdequate medicationSubstantial morbiditySymptom improvementInterventional treatmentMedication augmentationTreatment trialsCare treatmentClinical trialsDepressive disorderDiagnostic difficultiesLeading causeThe Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis
Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, Sos P, Wang G, Zarate CA, Sanacora G. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. American Journal Of Psychiatry 2017, 175: 150-158. PMID: 28969441, PMCID: PMC5794524, DOI: 10.1176/appi.ajp.2017.17040472.Peer-Reviewed Original ResearchConceptsIndividual participant dataLong-term safetySuicidal ideationKetamine effectsSingle doseParticipant dataSuicide itemOutcome measuresSystematic reviewIndividual Participant Data Meta-AnalysisLimited treatment optionsPrimary outcome measureSelf-reported outcome measuresData Meta-AnalysisIntravenous ketaminePublic health crisisKetamine administrationTreatment optionsQIDS-SRDepressed patientsDepressive symptomsIntervention studiesKetamineMeta-AnalysisSuicidal thoughts
2023
The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression
Lineham A, Avila-Quintero V, Bloch M, Dwyer J. The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression. Journal Of Child And Adolescent Psychopharmacology 2023, 33: 20-26. PMID: 36799961, DOI: 10.1089/cap.2022.0086.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntidepressive AgentsChildDepressionDepressive Disorder, MajorDepressive Disorder, Treatment-ResistantDouble-Blind MethodHumansKetamineMidazolamTreatment OutcomeConceptsTreatment-resistant depressionDepression symptom improvementAcute dissociative symptomsAntidepressant responseSymptom improvementRapid-acting antidepressant agentsSignificant associationDissociative symptomsLikelihood of responseDissociation symptomsMagnitude of associationDissociative effectsKetamine groupPediatric patientsCrossover trialPediatric populationAntidepressant agentsKetamine responseAdolescent patientsAdult studiesDepression responseSecondary data analysisTreatment responseDepressive symptomsTrial design
2017
Ketamine as a Treatment for Adolescent Depression: A Case Report
Dwyer JB, Beyer C, Wilkinson ST, Ostroff RB, Qayyum Z, Bloch MH. Ketamine as a Treatment for Adolescent Depression: A Case Report. Journal Of The American Academy Of Child & Adolescent Psychiatry 2017, 56: 352-354. PMID: 28335880, DOI: 10.1016/j.jaac.2017.01.006.Peer-Reviewed Case Reports and Technical NotesAdolescentDepressive Disorder, MajorHumansKetamineMalePsychiatric Status Rating ScalesTreatment OutcomeIntranasal Ketamine and Cognitive-Behavioral Therapy for Treatment-Refractory Obsessive-Compulsive Disorder
Adams TG, Bloch MH, Pittenger C. Intranasal Ketamine and Cognitive-Behavioral Therapy for Treatment-Refractory Obsessive-Compulsive Disorder. Journal Of Clinical Psychopharmacology 2017, 37: 269-271. PMID: 28121735, PMCID: PMC5321820, DOI: 10.1097/jcp.0000000000000659.Peer-Reviewed Original Research
2016
Time Course and Predictors of Suicidal Ideation During Citalopram Treatment in the STAR*D Trial.
Coughlin CG, Jakubovski E, Bloch MH. Time Course and Predictors of Suicidal Ideation During Citalopram Treatment in the STAR*D Trial. The Journal Of Clinical Psychiatry 2016, 77: e1262-e1269. PMID: 27631142, DOI: 10.4088/jcp.15m10075.Peer-Reviewed Original ResearchMeSH KeywordsAdultCitalopramDepressive Disorder, MajorDisease ProgressionFemaleFollow-Up StudiesHumansMaleMiddle AgedPersonality InventoryPsychometricsRisk FactorsSuicidal IdeationTime FactorsConceptsMajor depressive disorderCitalopram treatmentSuicidal ideationClinical predictorsClinical variablesSelective serotonin reuptake inhibitorsNonpsychotic major depressive disorderFirst-line treatmentBaseline clinical variablesSerotonin reuptake inhibitorsWeeks of treatmentSequenced Treatment AlternativesSide effect dataGreater likelihoodTime coursePhase 1Cardiac comorbiditiesNeurologic comorbiditiesBaseline characteristicsSedative medicationsReuptake inhibitorsTrial phase 1Clinical correlatesQuick InventoryDepressive disorder
2015
Anxiety Disorder-Specific Predictors of Treatment Outcome in the Coordinated Anxiety Learning and Management (CALM) Trial
Jakubovski E, Bloch MH. Anxiety Disorder-Specific Predictors of Treatment Outcome in the Coordinated Anxiety Learning and Management (CALM) Trial. Psychiatric Quarterly 2015, 87: 445-464. PMID: 26563229, DOI: 10.1007/s11126-015-9399-6.Peer-Reviewed Original ResearchConceptsSocial anxiety disorderAnxiety disordersCoordinated Anxiety LearningAnxiety LearningPost-traumatic stress disorderSelf-efficacy expectanciesPositive treatment expectanciesGeneralized anxiety disorderTreatment outcomesStress disorderTreatment expectanciesSpecific treatment needsSocial supportPanic disorderDisordersLearningSocioeconomic statusPredictorsSystematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder
Jakubovski E, Varigonda AL, Freemantle N, Taylor MJ, Bloch MH. Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder. American Journal Of Psychiatry 2015, 173: 174-183. PMID: 26552940, PMCID: PMC4975858, DOI: 10.1176/appi.ajp.2015.15030331.Peer-Reviewed Original ResearchMeSH KeywordsCitalopramDepressive Disorder, MajorDose-Response Relationship, DrugFluoxetineFluvoxamineHumansParoxetineSelective Serotonin Reuptake InhibitorsSertralineTreatment OutcomeConceptsSelective serotonin reuptake inhibitorsMajor depressive disorderSerotonin reuptake inhibitorsDepressive disorderHigh dosesTreatment responseReuptake inhibitorsBenefit of SSRIsEfficacy of SSRIsTolerability of SSRIsEffects of SSRIsRandomized placebo-controlled trialPlacebo-controlled trialStratified subgroup analysisTherapeutic dose rangeDose-response relationshipSSRI doseTolerability analysisMedication dosesSignificant positive associationSubgroup analysisMultiple time pointsDose categoriesMixed regression modelsCause dropoutsObsessive–compulsive symptoms are associated with psychiatric comorbidities, behavioral and clinical problems: a population-based study of Brazilian school children
Alvarenga PG, do Rosario MC, Cesar RC, Manfro GG, Moriyama TS, Bloch MH, Shavitt RG, Hoexter MQ, Coughlin CG, Leckman JF, Miguel EC. Obsessive–compulsive symptoms are associated with psychiatric comorbidities, behavioral and clinical problems: a population-based study of Brazilian school children. European Child & Adolescent Psychiatry 2015, 25: 175-182. PMID: 26015374, DOI: 10.1007/s00787-015-0723-3.Peer-Reviewed Original ResearchConceptsFamily History ScreenObsessive-compulsive disorderObsessive-compulsive symptomsSchool-aged childrenChild Behavior ChecklistUnaffected controlsPediatric-onset obsessive-compulsive disorderPresence of OCSPopulation-based studyComorbid psychiatric disordersMajor depressive disorderWell-Being AssessmentOCD groupBrazilian school childrenGroup of childrenPsychiatric comorbidityDepressive disorderClinical impactFunctional impairmentPsychiatric disordersClinical problemOCS groupDiagnostic groupsSignificant socio-demographic differencesSocio-demographic differencesSystematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors in Pediatric Major Depressive Disorder
Varigonda AL, Jakubovski E, Taylor MJ, Freemantle N, Coughlin C, Bloch MH. Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors in Pediatric Major Depressive Disorder. Journal Of The American Academy Of Child & Adolescent Psychiatry 2015, 54: 557-564. PMID: 26088660, DOI: 10.1016/j.jaac.2015.05.004.Peer-Reviewed Original ResearchMeSH KeywordsChildDepressive Disorder, MajorEarly Medical InterventionHumansPediatricsRandomized Controlled Trials as TopicSelective Serotonin Reuptake InhibitorsConceptsSelective serotonin reuptake inhibitorsPediatric major depressive disorderMajor depressive disorderSerotonin reuptake inhibitorsSSRI agentsReuptake inhibitorsPediatric depressionDepressive disorderAdult major depressive disorderFirst-line pharmacological treatmentEarly treatment responseIndividual patient dataStandardized mean differenceMDD trialsSSRI doseSSRI pharmacotherapyPlacebo groupAdult patientsSSRI responsePharmacological treatmentPharmacological trialsTreatment responsePooled estimatesPharmacological responseHigh dosesMr Jakubovski and Dr Bloch reply.
Jakubovski E, Bloch MH. Mr Jakubovski and Dr Bloch reply. The Journal Of Clinical Psychiatry 2015, 76: 327-8. PMID: 25830452, DOI: 10.4088/jcp.14lr09483a.Peer-Reviewed Original ResearchCitalopramDepressive Disorder, MajorFemaleHumansMaleOutcome Assessment, Health CareSelective Serotonin Reuptake Inhibitors
2014
Prognostic subgroups for remission and response in the Coordinated Anxiety Learning and Management (CALM) trial.
Kelly JM, Jakubovski E, Bloch MH. Prognostic subgroups for remission and response in the Coordinated Anxiety Learning and Management (CALM) trial. The Journal Of Clinical Psychiatry 2014, 76: 267-78. PMID: 25562579, PMCID: PMC4930076, DOI: 10.4088/jcp.13m08922.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdrenergic Uptake InhibitorsAdultAgedAnti-Anxiety AgentsAnxiety DisordersBenzodiazepinesCognitive Behavioral TherapyCombined Modality TherapyDepressive Disorder, MajorFemaleHumansMaleMiddle AgedOutcome Assessment, Health CarePanic DisorderPhobic DisordersPrognosisRemission InductionSelective Serotonin Reuptake InhibitorsSeverity of Illness IndexSex FactorsSocial ClassSocial SupportStress Disorders, Post-TraumaticYoung AdultConceptsLow socioeconomic statusCoordinated Anxiety LearningUsual careGeneralized anxiety disorderPosttraumatic stress disorderAnxiety disordersBaseline characteristicsPatient characteristicsPrognostic subgroupsAnxiety LearningSocioeconomic statusBaseline patient characteristicsCollaborative care interventionPrimary care settingPoor treatment outcomesCommunity treatment centersDSM-IV criteriaManagement trialsCognitive behavioral therapyLimited social supportExploratory moderator analysesMost patientsRemission criteriaComorbid depressionPrognostic outcomesPrognostic subgroups for citalopram response in the STAR*D trial.
Jakubovski E, Bloch MH. Prognostic subgroups for citalopram response in the STAR*D trial. The Journal Of Clinical Psychiatry 2014, 75: 738-47. PMID: 24912106, PMCID: PMC4471174, DOI: 10.4088/jcp.13m08727.Peer-Reviewed Original ResearchConceptsMajor depressive disorderBaseline clinical characteristicsClinical characteristicsTreatment successTreatment outcomesTreatment responseSide effectsSelective serotonin reuptake inhibitor (SSRI) pharmacotherapyEarly symptom improvementInitial clinical characteristicsOpen-label citalopramPrimary outcome measureFirst treatment phasePast treatment historySequenced Treatment AlternativesDSM-IV diagnosisTraditional psychiatric diagnosesDifferential treatment outcomesSSRI treatmentSymptom improvementMDD patientsMedication responsePoor responseDepressive disorderPrognostic subgroups
2013
Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive–compulsive disorder and a history of major depressive disorder
Niciu MJ, Grunschel B, Corlett PR, Pittenger C, Bloch MH. Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive–compulsive disorder and a history of major depressive disorder. Journal Of Psychopharmacology 2013, 27: 651-654. PMID: 23676198, DOI: 10.1177/0269881113486718.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnxietyDepressive Disorder, MajorFemaleHumansKetamineMiddle AgedObsessive-Compulsive DisorderSuicidal IdeationConceptsObsessive-compulsive disorderAntidepressant effectsPsychiatric comorbidityComorbid depressionNon-competitive N-methyl-D-aspartate (NMDA) receptor antagonistN-methyl-D-aspartate receptor antagonistTreatment-refractory obsessive-compulsive disorderAcute antidepressant effectsTreatment-resistant unipolarOpen-label trialSevere respiratory depressionAdverse neuropsychiatric effectsComorbid psychiatric disordersMinimal depressive symptomsOff-label useMajor depressive disorderStart of infusionRespiratory depressionIntravenous ketamineNeuropsychiatric effectsKetamine infusionBipolar depressionReceptor antagonistDepressive disorderSedative effects
2011
Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis
Bloch MH, Hannestad J. Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Molecular Psychiatry 2011, 17: 1272-1282. PMID: 21931319, PMCID: PMC3625950, DOI: 10.1038/mp.2011.100.Peer-Reviewed Original ResearchMeSH KeywordsDepressive Disorder, MajorDietary SupplementsFatty Acids, Omega-3HumansPublication BiasRandomized Controlled Trials as TopicConceptsPlacebo-controlled trialMajor depressive disorderBaseline depression severityDepression severityPublication biasMethodological qualityGreater baseline depression severityDocosahexaenoic acidEicosapentaenoic acidTrial methodological qualityPrimary outcome measureNon-significant benefitTreatment of depressionLow methodological qualityFatty acid treatmentTreat analysisDepressive disorderMajor depressionSources of heterogeneityOutcome measuresClinical measuresTreatment efficacySystematic reviewSecondary analysisStudy participantsThe Effect of Antidepressant Medication Treatment on Serum Levels of Inflammatory Cytokines: A Meta-Analysis
Hannestad J, DellaGioia N, Bloch M. The Effect of Antidepressant Medication Treatment on Serum Levels of Inflammatory Cytokines: A Meta-Analysis. Neuropsychopharmacology 2011, 36: 2452-2459. PMID: 21796103, PMCID: PMC3194072, DOI: 10.1038/npp.2011.132.Peer-Reviewed Original ResearchMeSH KeywordsAntidepressive AgentsBiomarkersClinical Trials as TopicCytokinesDepressive Disorder, MajorHumansInflammation MediatorsTreatment OutcomeConceptsMajor depressive disorderInflammatory cytokinesSerum levelsAntidepressant treatmentInterleukin-6Depressive symptomsIL-1βCytokine levelsDepressive episodeDiagnosis of MDDTumor necrosis factor alphaPharmacological antidepressant treatmentAntidepressant medication treatmentClasses of antidepressantsStratified subgroup analysisIL-1 betaNecrosis factor alphaNormalization of levelsReuptake inhibitorsMedication treatmentPharmacological treatmentSubgroup analysisBrain dysfunctionDepressive disorderFactor alpha
2010
Time-Lag Bias in Trials of Pediatric Antidepressants: A Systematic Review and Meta-Analysis
Reyes MM, Panza KE, Martin A, Bloch MH. Time-Lag Bias in Trials of Pediatric Antidepressants: A Systematic Review and Meta-Analysis. Journal Of The American Academy Of Child & Adolescent Psychiatry 2010, 50: 63-72. PMID: 21156271, PMCID: PMC3645909, DOI: 10.1016/j.jaac.2010.10.008.Peer-Reviewed Original ResearchConceptsSerotonin reuptake inhibitorsPlacebo-controlled trialTime-lag biasMajor depressive disorderYears of ageReuptake inhibitorsAntidepressant trialsPediatric depressionDepressive disorderTreatment respondersMAIN OUTCOMESystematic reviewMeta-AnalysisPositive findingsNegative findingsNegative trialsMedical literatureAntidepressantsTrialsPublication of findingsNegative resultsChild psychiatryEfficacyFindingsPublication time